Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granular Therapeutics
Sandwich, Kent, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Granular Therapeutics is developing granulocyte- and mast cell‑targeted biologics, including an anti‑c‑Kit/ENPP3 bispecific antibody and other mast cell–directed programs for systemic mastocytosis and broader mast cell driven inflammatory diseases; all disclosed assets are in discovery or preclinical development and no human clinical data have been reported yet.[1][3][6]
- Therapeutic areas
- HematologyImmunology
- Modalities
- BiologicBispecific monoclonal antibody
- Industry
- Biotech
02
Partnerships
Medicxi (backing/funding investor)[4][6]
Beyond the preview
Go deeper on Granular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granular Therapeutics.